UBS stock downgraded by Morgan Stanley on capital concerns

Morgan Stanley downgraded UBS Group AG (UBS) to Underweight from Equalweight, lowering the price target to CHF26.00 from CHF28.00, citing reduced buyback assumptions and a 5% average reduction in estimated EPS for 2025-2028. The downgrade reflects concerns that UBS will face a disadvantage compared to global competitors due to more stringent stress tests and capital requirements, despite UBS's efforts to optimize its capital structure. This contrasts with Jefferies' upgrade to Buy, anticipating positive earnings momentum, while Citi maintained a Neutral rating, highlighting concerns about UBS's earnings momentum compared to peers.

Analysis

UBS Group AG faces a mixed analyst outlook primarily driven by concerns over evolving capital requirements and their potential impact on shareholder returns and competitive positioning. Morgan Stanley downgraded UBS to Underweight, reducing its price target to CHF26.00 from CHF28.00, due to lowered buyback assumptions (to $3 billion from 2026 onwards) and an anticipated 5% average cut in estimated EPS for 2025-2028. This revised valuation considers excess capital above a higher 16.50% minimum, reflecting expectations that UBS's Group-level capital needs will rise to 19%, although Morgan Stanley anticipates 250 basis points of mitigating actions over time. The firm highlights that optimizing for these new capital constraints will be a lengthy process, potentially disadvantaging UBS against global peers with less stringent U.S. stress tests or no additional European capital demands. This contrasts with Jefferies, which upgraded UBS to Buy with a CHF37.00 price target, citing positive earnings momentum and an expected 15% return on tangible equity by 2027. Citi maintained a Neutral rating, expressing ongoing concerns about UBS's earnings momentum versus peers, while JPMorgan reiterated an Overweight rating (CHF37.00 target), acknowledging potential regulatory impacts. The Swiss Federal Council's proposed reforms could necessitate UBS raising up to $26 billion in new capital, primarily against foreign units. Despite these pressures, UBS plans to maintain its financial targets, including a 10% dividend increase and up to $3 billion in share buybacks by 2025, and has a strong track record of 14 consecutive years of dividend payments, with 17.7% growth in the last twelve months. InvestingPro data indicates two recent downward earnings revisions, yet assigns UBS a "GOOD" overall financial health score, with the stock trading near its Fair Value.

Key Decisions for Investors

• Investors should closely monitor UBS's ability to navigate the proposed stringent capital requirements and its progress in implementing mitigating capital optimization strategies, as this will be key to future profitability and shareholder returns.
• Given the divergent analyst ratings (Morgan Stanley's Underweight versus Jefferies' and JPMorgan's Overweight) and the stock trading near its InvestingPro Fair Value, a cautious approach is warranted, weighing the potential for earnings headwinds from regulatory pressures against management's commitment to shareholder returns and dividend growth.
• Consider the extended timeline for UBS to adapt to new capital constraints, which may create a period of uncertainty and potential underperformance relative to peers less affected by similar regulatory stringency, before making new or adjusting existing positions.